Abiraterone Acetate Tablets 250mg for prostate cancer
Abirataj is a prescription medicine that is used along with prednisone. Abirataj is used to treat men with prostate cancer that has spread to other parts of the body. Abirataj is not for use in women. Abiraterone acetate (Abirataj) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α‑hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and andro stenedione, respectively, by C17, 20 lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. Abirataj decreased serum testosterone and other androgens in patients in the placebo‑controlled clinical trial. It is not necessary to monitor the effect of Abirataj on serum testosterone levels. Changes in serum prostate specific antigen (PSA) levels may be observed but have not been shown to correlate with clinical benefit in individual patients.
Abirataj is indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC)read more
Recommended Dose For Metastatic CRPC
The recommended dose of abirataj is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.
Like all medicines, this medicine can cause side effects, although not everybody gets them.. Stop taking Abiraterone Acetate Tablet and see a doctor immediately if you notice any of the following side effects.read more
Drugs That Inhibit Or Induce CYP3A4 Enzymes
In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%.
Abirataj may cause hypertension, hypokalemia, and fluid retention increased mineralocorticoid levels resulting from CYP17 inhibition.Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month.read more
Abirataj tablets are available in 500 mg film-coated tablets, 250 mg film-coated tablets and 250 mg uncoated tablets with the following inactive ingredients.
Abiraterone Acetate Tablets is an androgen biosynthesis inhibitor which comes under the strength of 250 mg in each tablet.Read More
Patient benefired from generics
Percent off cost the brand medicine
Hospital and leading oncology care
Continuous off Low Income Options